{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T02:54:23Z","timestamp":1785207263994,"version":"3.55.0"},"reference-count":25,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"vor","delay-in-days":17,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Ventilator\u2010associated pneumonia (VAP) caused by gram\u2010negative bacteria is associated with significant complications, mortality, and resource utilization. Over the past decade, there has been growing interest in using fosfomycin to treat multidrug\u2010resistant gram\u2010negative infections, particularly when limited viable options remain. This study aimed to investigate the efficacy of inhaled colistin\/fosfomycin as an adjunctive treatment for VAP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this triple\u2010blind clinical trial, participants with VAP caused by extensively drug\u2010resistant (XDR)\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      were randomly assigned to two groups. Both groups received meropenem (2\u2009g as a 4\u2009h extended infusion every 8\u2009h) and intravenous colistin (9 million IU loading dose, followed by 4.5 million IU every 12\u2009h). The control group was treated with inhaled colistin (1 million IU every 8\u2009h), while the intervention group received a combination of inhaled colistin (1 million IU every 8\u2009h) and fosfomycin (80\u2009mg every 12\u2009h). Clinical pulmonary infection score (CPIS) was measured at baseline and upon completion of the intervention. Acute kidney injury (AKI) rates during treatment, as well as clinical response and microbiological outcomes, were compared between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      While the differences were not statistically significant (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.19), the failure rate was lower in the colistin\/fosfomycin group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093; 7.7%) compared to the colistin group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20097; 18.9%). The colistin\/fosfomycin group exhibited a higher microbiological response rate (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919; 48.7%) than the colistin group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200913; 35.1%), although the difference did not reach statistical significance (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.23). Both groups showed a significant reduction in CPIS; however, there was no statistically significant difference in procalcitonin levels or CPIS changes between the groups. Treatment duration was significantly shorter in the colistin\/fosfomycin group (8.97\u2009\u00b1\u20092.12 days) compared to the colistin group (14.06\u2009\u00b1\u20093.32 days) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The incidence of AKI was similar between the groups, with 15 cases (38.5%) in the colistin\/fosfomycin group and 13 cases (35.1%) in the colistin group (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.76).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The study demonstrated that the addition of inhaled colistin\/fosfomycin to the treatment regimen may result in faster recovery and shorter treatment duration for patients with VAP caused by XDR\n                      <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.71670","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:02:31Z","timestamp":1766127751000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Inhaled Colistin\/Fosfomycin as an Adjunctive Treatment for Ventilator\u2010Associated Pneumonia: A Preliminary Study"],"prefix":"10.1002","volume":"8","author":[{"given":"Atousa","family":"Hakamifard","sequence":"first","affiliation":[{"name":"Infectious Diseases and Tropical Medicine Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Mohammadi","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Tropical Medicine Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Homayouni","sequence":"additional","affiliation":[{"name":"Research and Development Department Goldaru Pharmaceutical Company Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Khorvash","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Tropical Medicine Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Anesthesiology and Critical Care Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz","family":"Ataei","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Tropical Medicine Research Center Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7136-3069","authenticated-orcid":false,"given":"Mahnaz","family":"Momenzadeh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Practice Isfahan University of Medical Sciences Isfahan Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,18]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.4103\/1735-5362.363594"},{"issue":"5","key":"e_1_2_12_3_1","first-page":"288","article-title":"Clinical Response and Outcome of Pneumonia Due to Multi\u2010Drug Resistant Acinetobacter baumannii in Critically Ill Patients","volume":"8","author":"Shojaei L.","year":"2016","journal-title":"Iranian Journal of Microbiology"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.5812\/archcid.111084"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.026"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30099-9"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.4103\/ejcdt.ejcdt_25_17"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac142"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-020-06036-z"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02435-13"},{"key":"e_1_2_12_11_1","unstructured":"M. P.Weinstein J. B.Patel A. M.Bobenchik F.Marcelo et al. \u201cGalas Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing. M100 \u201d 29th published 2019 https:\/\/clsi.org\/media\/2663\/m100ed29_sample.pdf."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.6812"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/429323"},{"key":"e_1_2_12_15_1","unstructured":"P. S.Tharavichitkul C.Sanguanlikitkul M.Boonchoo et al. \u201cIn Vitro Synergistic Effects of a Combination of Fosfomycin and Colistin Against Metallo\u2010\u03b2\u2010Lactamase\u2010ProducingAcinetobacter baumannii \u201d vol. 15 In 31st Annual Meeting of the Infectious Disease Association of Thailand Chonburi Thailand 2005."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02061.x"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019048-200106000-00004"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-015-0133-5"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70325-1"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1089\/sur.2006.051"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/147.5.1279"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-017-1916-6"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu706"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53714-0"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics13030287"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2024.03.010"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.71670","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:49:35Z","timestamp":1776167375000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.71670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/hsr2.71670"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.71670","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71670"}}